An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704

Trial Profile

An Open-Label Extension Study of Patients With Late-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU02704

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 May 2017

At a glance

  • Drugs Alglucosidase alfa (Primary)
  • Indications Glycogen storage disease type II
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Genzyme Europe; Sanofi Genzyme
  • Most Recent Events

    • 06 May 2017 New trial record
    • 28 Apr 2017 Results assessing long-term efficacy of alglucosidase alfa in late-onset pompe disease patients from LOTS study, its open-label extension and Pompe Registry, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 25 Nov 2008 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top